Status:
UNKNOWN
TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study
Lead Sponsor:
NovoCure Ltd.
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
This non-interventional study aims to investigate change over time in cognitive function, sleep quality, and activity in daily life as important determinants of QoL in a large cohort of GBM patients i...
Detailed Description
Glioblastoma (GBM) is the most common malignant primary tumor of the brain with an annual incidence of approximately 3/100.000. Since 2005 the treatment for newly diagnosed GBM consisted of maximal su...
Eligibility Criteria
Inclusion
- min.18 years of age
- Newly diagnosed, histologically confirmed GBM
- Patient after completion of radiochemotherapy but within first 3 cycles of first-line tumor-specific maintenance chemotherapy
- Clinical indication of treatment with NovoTTF-200A System (Optune®) according to IFU and medical guidelines
- Signed informed consent
Exclusion
- Any foreseeable deviation from the IFU of NovoTTF-200T Device
Key Trial Info
Start Date :
December 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04717739
Start Date
December 30 2021
End Date
February 1 2025
Last Update
January 10 2023
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Aachen
Aachen, Germany, 52074
2
Klinikum Aschaffenburg-Alzenau
Aschaffenburg, Germany, 63739
3
Universitätsklinikum Augsburg (AöR)
Augsburg, Germany, 86156
4
Universitätsklinikum Bonn
Bonn, Germany, 53127